Rosacea Treatments Market Overview

Rosacea Treatments Market Size Was Valued at USD 1.92 Billion in 2023, and is Projected to Reach USD 4.08 Billion by 2032, Growing at a CAGR of 8.75% From 2024-2032.

Rosacea is a long-lasting skin disorder that leads to facial redness, lumps, and noticeable blood vessels. Although rosacea cannot be cured, there are various treatments available to manage symptoms and enhance the look of your skin.

• Topical medications provide specific solutions. Metronidazole and azelaic acid combat both inflammation and bacteria as antibiotics. Brimonidine gel decreases the size of blood vessels to lessen redness, while ivermectin decreases inflammation and could target mites associated with rosacea. In extreme situations, doxycycline may be recommended as an oral antibiotic for controlling inflammation. Isotretinoin, a potent drug with possible adverse reactions, is only used for severe conditions that do not improve with alternative therapies and needs monitoring by a dermatologist.
• Advancements in digital health treatments are pushing forward progress in Rosacea Treatment. The management of rosacea is evolving due to the increased utilization of telemedicine and digital healthcare options, enabling remote consultations, follow-ups, and patient monitoring. This development boosts patient adherence and enhances the availability of specialized treatments, particularly in underprivileged regions. The application of digital technologies in treating rosacea offers the potential for market growth due to its more user-friendly and practical approach.

Market Dynamics and Key Factors of Rosacea Treatment

Drivers

Increasing Prevalence of Acne Diseases

According to dermatologists, the incidence rates of rosacea are very high, and it tends to be more common in fair-skinned individuals. During the assessment of rosacea in individuals, the diversity in the population should be taken into consideration. For instance, according to Howards Medical School research, the rosacea prevalence rate in all of the women, regardless of the ethnic background was 9.6 percent. At the same time, the prevalence rate in Caucasian women alone was 16% compared to the rates found in Ireland and Sweden. 

Increasing Demand for Combination Therapies

The market faces high generic penetration, due to multiple patent expiries and off-label usage of medicines. Rosacea is treated with a variety of acne treatments, including benzoyl peroxide, azelaic acid, and sulfur compounds. Even though the majority of medicines are topical or oral, there is a substantial paradigm shift going, with treatment choices progressively leaning toward combination therapy for better results.

Increasing Inclination of Drug Manufacturers Towards Patient Convenience

Prevalence of first-line treatments and convenience of patients for oral medications across the globe is considered to drive the growth of the market. Moreover, oral and topical medications are administered in combination, on a case-to-case basis, and depending upon disease severity. In such circumstances, oral medication is gradually discontinued, while topicals are used as maintenance therapy. Thereby, drug manufacturers are increasingly inclining towards patient convenience and compliant medications.

Increasing Availability of Rosacea Medication Over the Counter (OTC)

The dermatology OTC drugs market is driven by the advent of innovative drugs. The product innovations in OTC dermatology medications have increased the demand for OTC drugs. Several effective dermatology medications are now available OTC. The number of individuals suffering from rosacea is high but, only a few seek out the help of a healthcare provider to address these issues. With a growing trend among consumers to self-treat, the demand for OTC mediations is increasing.

Restraints

High Cost for The Treatment

The high cost of topical creams and medications is the main restraining factor for the development of the rosacea treatment market. In America, more than 2.16 million sought medical treatments for rosacea in 2020 which cost approximately US$ 215.71 million. Furthermore, patients and their caregivers have experienced substantial productivity loss with a total of 157.3 million USD. On the other hand, the total medical cost for rosacea treatments is a lot less than skin concerns, ulcers, and cutaneous infections

Side Effects Associated with OTC Medication

Certain rosacea treatments can cause severe allergic reactions. To avoid such a situation, it is necessary to take proper guidance before trying OTC dermatology products. The FDA has also warned against the use of OTC medications. For instance, the FDA issued an alert on the usage of certain OTC medications that can cause allergic reactions.

Opportunities

The dramatic shift in lifestyle and the changing environmental conditions due to global warming has boosted the spread of several skin disorders. Ultraviolet radiation Can exacerbate or initiate rosacea. People living in the European and American regions are mostly affected by this disease as they have a very bright skin tone. Market players can target these regions and launch new products in this region that can help reduce the complications associated with rosacea. Market players can conduct voluntary trials in this region to formulate solutions that can suit the skin condition of patients in this region. Moreover, the government in these regions is also supporting the expansion of the rosacea treatment market by providing funds for R&D activities. For instance, the USA healthcare department has funded 70 billion USD in the year 2020 to the American Academy of Dermatology and Skin diseases for rosacea and acne treatment and research and development on the medications used for disease. Moreover, the Food and Drug Administration of the USA has also funded 200 million USD for new medications used for acne.

Market Segmentation

Segmentation Analysis of Rosacea Treatment Market

Depending on the disease type, Erythematotelangiectatic {ETR} rosacea dominated the market and is expected to do the same in the forecast period. ETR rosacea is the most common type affecting both genders. Near about 80% of the total population affected by rosacea is suffering from ETR. Individuals with ETR are mainly affected by facial redness, visible surface blood vessels, and flushing. 'Erythema' is the medical term dermatologists use for redness, 'telangiectasias' are visible surface blood vessels. Patients with this type of rosacea experience a prolonged flushing period, a burning and stinging sensation after being exposed to certain environmental factors.

Depending on the treatment type, the laser therapy segment is expected to lead the rosacea treatment market in the analysis period. The heat from the light wavelength is utilized by lasers to treat the tiny, swollen red blood cells. This is a painless therapy and the results last for years. Laser therapy improves the texture of the skin and patients observe a 50-70 % reduction in their symptoms after one to three treatments. Laser therapy has fewer side effects and has long-lasting effects thus, driving the growth of the segment.

Depending on the distribution channel, the commercial drug store segment is anticipated to lead the rosacea treatment market over the projected period. There has been a significant rise in the number of patients suffering from rosacea even though, most people prefer OTC to treat the symptoms. The large-scale presence of commercial drug stores and the discounts offered by them on different medications are the essential factors expected to propel the expansion of the rosacea market.

Regional Analysis of Rosacea Treatment Market

The European region is forecasted to dominate the rosacea treatment market during the forecast period. This skin condition is the most common found in the individuals living in this region. Epidemiological studies have shown that 10% of the Swedish population have rosacea followed by the French and German population, each accounting for 2-3% prevalence. According to the European Academy of Dermatology and Venerology (EADV), near about half (47.9%) of the total European population experienced at least one dermatological condition in 2021. Atopic dermatitis (eczema) (5.34%), and acne (5.49%) were the second most and third most skin disorders respectively. Thus, the growing number of skin-related disorders is expected to drive the growth of the rosacea market in this region.

The North American region is anticipated to have the second-highest share of the rosacea treatment market over the forecast period. According to the American Academy of Dermatology, rosacea affects at least 14 million adults in the United States, or around one out of every ten people. The National Rosacea Society (NRS) estimates that there are now 16 million people living with Rosacea. Despite its relatively high prevalence, rosacea is frequently misdiagnosed or left undiagnosed. The consequence is needless suffering for many patients. The presence of prominent market players and the launch of innovative products to treat the skin conditions of patients are the essential factors expected to consolidate the development of the market in this region.

The rosacea treatment market in the Asia-Pacific region is expected to develop at a significant growth rate in the analysis period. The changing lifestyle, rise in pollution, and global warming are factors responsible for the development of rosacea in people inhabiting this region. Rapid urbanization and industrialization have triggered the factors that may cause rosacea in a certain group of individuals. The growing adoption of cosmetics and the increasing smoker's population may drive the incidence rates of rosacea thus, strengthening the growth of the market in this region.  

Players Covered in Rosacea Treatments market are :

• Nestle Skin (US)
• GlaxoSmithKline plc (UK)
• Viatris Inc. (US)
• Body Glide (US)
• Sun Pharma (India)
• Perrigo (Ireland)
• Bayer (Germany)
• Pfizer (US)
• Teva (Israel)
• Allergan (Ireland)
• Bausch Health (Canada)
• Almirall (Spain)

Recent Industry Developments in Rosacea Treatment Market

• 03 July 2024 GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their respective mRNA development activities.  Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine candidates for seasonal influenza and COVID-19 in phase II and avian influenza in phase I clinical development. All candidates are based on CureVac’s proprietary second-generation mRNA backbone. Data generated to date for these candidate vaccines are promising and demonstrate their potential to be best-in-class new vaccines.

• June 21, 2024, Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name “Voltapraz”. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.